近一年多来,艾伯维频频出手,通过引进或并购的方式扩充自己的TCE及In vivo CAR-T管线及平台。我们可以怀疑艾伯维的研发能力,但我们要相信其战略眼光。读懂艾伯维的研发策略能帮助国内企业更好的布局相关产品及技术。艾伯维的修美乐(TNFα抑制剂)曾经霸榜全球药王11年,但终究由于专利到期而走下了神坛。为了填补专利悬崖带来的销售空白,艾伯维提前十多年布局,通过自研+引进的方式成功的开发出乌帕替尼...
Source Link近一年多来,艾伯维频频出手,通过引进或并购的方式扩充自己的TCE及In vivo CAR-T管线及平台。我们可以怀疑艾伯维的研发能力,但我们要相信其战略眼光。读懂艾伯维的研发策略能帮助国内企业更好的布局相关产品及技术。艾伯维的修美乐(TNFα抑制剂)曾经霸榜全球药王11年,但终究由于专利到期而走下了神坛。为了填补专利悬崖带来的销售空白,艾伯维提前十多年布局,通过自研+引进的方式成功的开发出乌帕替尼...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.